Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22289770 | 0.92 | CD44 (0.56) | CD44CYP3A4TDP1TSHRNPC1 | |
| SCHEMBL30839806 | 0.92 | CD44 (0.62) | CD44CYP3A4TDP1TSHRNPC1 | |
| SCHEMBL3790203 | 0.92 | CD44 (0.62) | CD44CYP3A4TDP1TSHRNPC1 | |
| Hydrochloric Acid SCHEMBL11680714 | 0.90 | CD44 (0.59) | CD44CYP3A4TDP1TSHRNPC1 | |
| SCHEMBL3787337 | 0.86 | CD44 (0.62) | CD44CYP3A4TDP1TSHRNPC1 | |
| SCHEMBL29414659 | 0.86 | CD44 (0.62) | CD44CYP3A4TDP1TSHRNPC1 | |
| SCHEMBL3794848 | 0.86 | CD44 (0.62) | CD44CYP3A4TDP1TSHRNPC1 | |
| SCHEMBL3785981 | 0.82 | PLA2G7 (0.61) | CD44CYP3A4TDP1TSHRNPC1 | |
| SCHEMBL2277338 | 0.81 | MYC (0.50) | CD44CYP3A4TDP1TSHRNPC1 | |
| SCHEMBL1497244 | 0.81 | ALDH1A1 (0.50) | CD44CYP3A4TDP1TSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-11739103-B2 | Processes for preparing a pan-JAK inhibitor and related intermediate compounds | Theravance Biopharma R&D LP, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220112219-A1 | PROCESSES FOR PREPARING A PAN-JAK INHIBITOR AND RELATED INTERMEDIATE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2022-04-14 | — | — | US | disclosed |
| EP-3746079-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | Bayer Aktiengesellschaft (DE) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019149637-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | WO | disclosed |
| WO-2018170275-A1 | CARBOXYLIC DIARYTHIAZEPINEAMINES AS MIXED MU-AND DELTA-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-09-20 | — | — | WO | disclosed |
| WO-2017220431-A1 | FUSED PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2017-12-28 | — | — | WO | disclosed |
| EP-2699551-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | Glaxosmithkline LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| EP-2643321-A1 | IMIDAZO [1,2-B]PYRIDAZINE AND IMIDAZO [4,5-B]PYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012143415-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012069202-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL,S.A. (ES) | 2012-05-31 | — | — | WO | disclosed |
| EP-2421870-A2 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010124042-A2 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | WO | disclosed |
| EP-2121703-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| EP-2094662-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | Astellas Pharma Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008072784-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008020799-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
| EP-1730114-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005087746-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112219-A1 | PROCESSES FOR PREPARING A PAN-JAK INHIBITOR AND RELATED INTERMEDIATE COMPOUNDS | JAK1, JAK3, JAK2 | CD44 4572/4885CYP3A4 825/4885TDP1 2495/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | CD44 1659/4885CYP3A4 4672/4885TDP1 3110/4885 |
| US-11739103-B2 | Processes for preparing a pan-JAK inhibitor and related intermediate compounds | JAK1, JAK3, JAK2 | CD44 4572/4885CYP3A4 825/4885TDP1 2495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.